A central component of COVID-19 disease containment strategies will be scaled-up testing and self-isolation/quarantine as applicable \[[@CIT0001], [@CIT0002]\]. This strategy requires active identification of case patients, contact tracing, and testing of people within their networks. Successful implementation of this strategy will require widespread access to testing; substantial efforts are underway to increase SARS-CoV-2 virus testing capacity in the United States and globally. In addition to access (eg, supply), success of testing strategies will be contingent on the extent to which tests are acceptable to patients (eg, demand). Case identification and contact tracing efforts depend greatly on willingness to test among patients experiencing COVID-19 disease--like symptoms. To inform patient isolation strategy, those who have tested positive should be tested again during follow-up care (the US Centers for Disease Control and Prevention recommends 2 consecutive tests collected ≥24 hours apart) if supplies and laboratory capacity are sufficient; alternatively, a symptom-based strategy is recommended \[[@CIT0003]\]. Patient willingness to seek testing is especially critical because many persons infected with SARS-CoV-2 may experience only mild symptoms: In Italy, 30% of diagnosed cases have been classified as mildly symptomatic \[[@CIT0004]\], although such estimates may be an undercount due to the likely lower frequency of test-seeking in this group. For other infectious diseases, self-collection procedures have long been practiced \[[@CIT0005], [@CIT0006]\], have been identified as highly acceptable and preferred to in-clinic procedures \[[@CIT0007]\], and have diagnostic metrics comparable to health care worker specimen collection \[[@CIT0008], [@CIT0009]\].

Calls for home-based specimen collection or drive-through specimen collection models to address SARS-CoV-2 virus test scale-up have cogently argued that these approaches have the benefit of (1) avoiding burdening hospitals at a critical time, (2) avoiding potential nosocomial infections (the risk of acquiring disease from clinical or laboratory settings), (3) likely lowering costs, and (4) potentially achieving rapid scale-up due to laboratory centralization \[[@CIT0010], [@CIT0011]\]. One additional benefit of home specimen collection might be that supply chain issues, such as stock-outs of swabs or personal protective equipment, could be alleviated if nontraditional specimens such as saliva or nontraditional locations such as home settings prove sufficient.

Drive-through SARS-CoV-2 virus testing sites already exist \[[@CIT0010]\], and a number of laboratories are working to additionally validate home-based self-specimen collection for SARS-CoV-2 testing. Protocols for the self-collection of specimens at home for SARS-CoV-2 testing are currently being explored \[[@CIT0012]\]. For instance, 2 saliva-based SARS-CoV-2 virus tests have recently received Emergency Use Authorization from the US Food and Drug Administration for home-based specimen collection \[[@CIT0013], [@CIT0014]\]. These protocols involve persons being mailed specimen collection materials and instructions, self-collection of specimens at home, and return of specimens to a central laboratory using a supplied mailer. We conducted an online survey to assess patient willingness to use the following SARS-CoV-2 testing modalities for clinical care: home-based specimen collection, drive-through testing, and clinic-based testing. We hypothesized that persons would be more willing to use home-based and drive-through specimen collection modalities compared with clinic-based modalities.

METHODS {#s1}
=======

We recruited potential participants using online social media advertisements from March 27 to April 1, 2020. To be eligible, respondents had to be 18 years of age or older. Given the disproportionate impact of COVID-19 on communities of color, on the final day of data collection eligibility criteria were adjusted to screen out non-Hispanic white respondents in an effort to increase minority representation in the sample. Participants completed a nonincentivized online survey after being recruited from social media sites with banner advertisements requesting participation in COVID-19 survey research. Survey measures included previously published demographic items \[[@CIT0015]\], COVID-19 disease knowledge \[[@CIT0016]\], COVID-19 disease stigma items \[[@CIT0016]\], and a list of COVID-19 disease symptoms based on several sources \[[@CIT0017]\]. Regions were defined according to US Census Bureau classifications of states. To understand whether responses were differential by state COVID-19 burden, we created a binomial variable, with high-burden states defined as having \>99 cases per 100 000 population (NY, NJ, MA, LA, CT) at the time of the survey; these states accounted for over half of all COVID-19 cases at that time \[[@CIT0020]\]. We developed a series of questions about willingness to use different testing modalities, each rated with a 5-point Likert scale (1 = strongly disagree to 5 = strongly agree). The questions were based on home test willingness questions we have previously used in HIV prevention research \[[@CIT0007]\]. Definitions for each testing modality were: "A home saliva sample would involve you spitting in a tube and sending it to a certified laboratory," "A home throat swab would involve you using a throat swab and sending it into a certified laboratory," "A drive-through site for throat swab would involve your traveling to a drive-through facility in your car to have a healthcare worker collect the swab," and "A laboratory throat swab would involve your traveling to a laboratory facility in a clinic or private laboratory to have a healthcare worker collect the swab." Other questions assessed whether persons rated themselves as more likely to seek testing if the option to collect specimens at home for mail-in testing were available \[[@CIT0019]\]. The full text of survey items can be seen in the [Supplementary Data](#sup1){ref-type="supplementary-material"}. All participants completed a written electronic consent procedure, and study procedures were approved by the Emory University Institutional Review Board.

[Figure 1](#F1){ref-type="fig"} displays a flowchart of study participation. [Figure 2](#F2){ref-type="fig"} displays the proportion of respondents selecting each willingness option. [Table 1](#T1){ref-type="table"} displays demographics and related variables by mean Likert scale values using Kruskall-Wallace tests for nonordered categorical variables and Spearman rank tests for ordinal variables, adjusted for multiple testing using Holm-Bonferroni correction. Cohen's *d* effect size was used to guide interpretation of effect size using standard interpretations. Study reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology criteria for cross-sectional studies \[[@CIT0021]\].

![Study participation flowchart. ^a^Some participants were disqualified based on both age and race/ethnicity criteria (n = 11). ^b^On the final day of data collection, targeting strategies and eligibility criteria were adjusted to disqualify non-Hispanic white participants in an effort to increase minority representation in the sample given the disproportionate impact of COVID-19 on communities of color. ^c^Screeners were considered partial and removed from the final analysis sample if participants did not complete all primary outcome questions.](ofaa269f0001){#F1}

![Willingness to seek laboratory testing for SARS-CoV-2 under different specimen collection scenarios. For home specimens, instructions clarified that specimens would be collected at home and mailed to a central laboratory for testing.](ofaa269f0002){#F2}

###### 

Willingness to Seek Testing for SARS-CoV-2 if Feeling Ill, by Sociodemographic and COVID-19 Factors

                                                                     Home: Saliva Sample   Home: Throat Swab   Drive-through: Throat Swab   Clinic: Throat Swab                     
  ----------------------------------------------------------- ------ --------------------- ------------------- ---------------------------- --------------------- ----- ----- ----- -----
  Overall                                                     1435   4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.7   1.4
  Gender                                                                                                                                                                            
   Female                                                     761    4.6                   0.8                 4.5                          0.9                   4.0   1.3   3.6   1.4
   Male                                                       536    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.8   1.3
   Other                                                      36     4.7                   0.8                 4.6                          0.9                   4.1   1.0   3.9   1.1
  Age                                                                                                                                                                               
   18--29 y                                                   560    4.5                   0.9                 4.4                          1.0                   3.9   1.3   3.7   1.3
   30--49 y                                                   391    4.6                   0.8                 4.6                          0.9                   4.1   1.2   3.7   1.4
   50--64 y                                                   289    4.6                   0.7                 4.5                          0.9                   4.0   1.2   3.5   1.4
   ≥65 y                                                      194    4.6                   0.8                 4.5                          0.8                   4.0   1.2   3.6   1.3
  Race/ethnicity                                                                                                                                                                    
   Hispanic                                                   548    4.6                   0.8                 4.5                          0.9                   4.0   1.3   3.8   1.4
   Asian/Pacific Islander                                     52     4.7                   0.6                 4.6                          0.7                   4.0   1.1   3.9   1.2
   Non-Hispanic black                                         158    4.5                   0.9                 4.4                          1.0                   3.9   1.3   3.7   1.4
   Non-Hispanic white                                         587    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.6   1.3
   Other                                                      90     4.4                   1.0                 4.2                          1.2                   3.7   1.4   3.5   1.4
  Education                                                                                                                                                                         
  College or higher                                           629    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.7   1.4
  Some college/Associate's                                    382    4.7                   0.7                 4.6                          0.8                   4.1   1.2   3.8   1.3
  High school/GED                                             175    4.5                   0.8                 4.4                          1.0                   3.9   1.3   3.6   1.4
  Did not finish high school                                  27     4.6                   0.6                 4.6                          0.8                   3.9   1.2   3.8   1.4
  Annual income                                                                                                                                                                     
   \<\$24 000                                                 294    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.8   1.3
   \$24 000--\<\$50 000                                       276    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.7   1.3
   \$50 000--\<\$75 000                                       203    4.6                   0.8                 4.5                          0.9                   4.1   1.2   3.7   1.3
   \>\$75 000                                                 268    4.8                   0.6                 4.6                          0.8                   4.1   1.2   3.7   1.4
   Don't know                                                 91     4.6                   0.7                 4.5                          0.8                   3.9   1.2   3.6   1.3
  Region                                                                                                                                                                            
   Midwest                                                    280    4.6                   0.7                 4.6                          0.8                   4.0   1.3   3.7   1.4
   Northeast                                                  251    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.8   1.4
   South                                                      540    4.5                   0.9                 4.4                          1.0                   3.9   1.3   3.6   1.4
   West                                                       360    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.8   1.3
  High-burden state (NY, NJ, MA, LA, CT)^c^                                                                                                                                         
   No                                                         1234   4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.7   1.4
   Yes                                                        200    4.6                   0.8                 4.5                          0.9                   4.0   1.3   3.8   1.4
  How likely do you think it is that you have COVID-19 now?                                                                                                                         
   Very unlikely                                              356    4.5                   1.0                 4.4                          1.0                   3.7   1.4   3.5   1.5
   Unlikely                                                   661    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.7   1.3
   Somewhat likely                                            324    4.7                   0.7                 4.6                          0.8                   4.2   1.1   3.8   1.2
   Likely/very likely                                         81     4.6                   0.9                 4.5                          1.0                   4.1   1.3   3.7   1.5
  Stigma Index Score                                                                                                                                                                
   0                                                          722    4.6                   0.8                 4.5                          0.9                   4.1   1.2   3.8   1.3
   1--2                                                       525    4.6                   0.8                 4.5                          0.9                   3.9   1.3   3.6   1.4
   3+                                                         106    4.4                   1.1                 4.4                          1.1                   3.8   1.4   3.5   1.5
  Knowledge Index Score                                                                                                                                                             
   \<12                                                       273    4.5                   0.9                 4.4                          1.0                   3.9   1.3   3.6   1.4
   12--13                                                     824    4.6                   0.8                 4.5                          0.9                   4.0   1.2   3.7   1.3
   14                                                         237    4.6                   0.8                 4.5                          1.0                   4.0   1.2   3.6   1.4
  Symptoms                                                                                                                                                                          
   ≥1 symptom                                                 747    4.6                   0.7                 4.5                          0.9                   4.1   1.2   3.8   1.3
   None                                                       688    4.5                   0.9                 4.4                          1.0                   3.9   1.3   3.6   1.4

^a^All willingness items used a 5-point Likert scale: 1 = strongly disagree to 5 = strongly agree.

^b^There were no significant differences in testing scenario scores by any variable considered (eg, home saliva specimen score differences across gender, age, etc.) after Bonferroni-Holms correction for multiple hypothesis testing.

^c^High-burden states as of the time of the survey (April 1, 2020), defined as \>99 cases/100 000 population.

RESULTS {#s2}
=======

From 4593 persons initiating the survey screener, 1260 were ineligible, 1886 did not consent or provided only partial survey responses, and 1435 completed all willingness items for the analysis data set ([Figure 1](#F1){ref-type="fig"}). The sample was 39% (n = 560) aged 18--29, 27% (391) aged 30--49, 20% (289) aged 50--64, and 14% (194) aged 65 or older. Females comprised 57% (761), males 40% (536), and other gender identity 3% (36). Overall 41% (587) were non-Hispanic white, 38% (548) were Hispanic, 11% (158) were non-Hispanic black, 4% (52) were Asian/Pacific Islander, and 6% (90) were Native American/Alaska Native or identified as mixed race or other non-Hispanic. COVID-19 knowledge was high, with 75% (997) answering at least 12 of 14 knowledge questions correctly, and COVID-19 stigma was moderate, with 46% (631) answering at least 1 of 4 stigma questions in a stigmatizing direction. A majority of 72% (1017) thought they were unlikely to have COVID-19, although 52% (747) reported 1 or more of a broad range of potential COVID-19 symptoms.

Home specimen collection solutions were most preferred, with 92% (1314/1435) of participants agreeing or strongly agreeing that they would provide a saliva specimen, and 88% (1258/1435) agreeing that they would provide a throat swab ([Figure 2](#F2){ref-type="fig"}). There was attenuated willingness for drive-through swab testing (71%, 1026/1435) and substantially attenuated willingness for clinic or laboratory throat swab (60%, 854/1435). Differences in mean willingness scores across testing modalities were all significant (*P* \< .001), with a very small effect size for home saliva testing compared with home throat swab testing (*d* = 0.12), a medium effect size for home saliva testing compared with drive-through testing (*d* = 0.55), and a large effect size for home saliva testing compared with clinic-based testing (*d* = 0.81). We found highly similar willingness to seek testing for COVID-19 follow-up care ([Figure 2](#F2){ref-type="fig"}) and identical significance and effect size findings ([Supplementary Data](#sup2){ref-type="supplementary-material"}). Willingness to seek testing for diagnosis and care within each testing modality was remarkably consistent across all covariates in the analysis, with no differences across age groups, races/ethnicities, COVID-19 stigma scores, COVID-19 knowledge scores, COVID-19 symptomology, region, or state-level COVID burden ([Table 1](#T1){ref-type="table"}).

To directly assess the potential behavioral change associated with different home care testing modalities, we asked participants whether they would be more likely, equally as likely, or less likely to seek testing for COVID-19 disease if at-home specimen collection options were available. Relative to availability of a drive-through modality, 65% (933) noted that they would be more likely to test if at-home specimen collection were available, 32% (459) noted no difference, and 3% (43) noted lower likelihood. Relative to availability of a clinic- or lab-based modality, 68% (970) noted that they would be more likely to test if at-home specimen collection were available, 29% (418) noted no difference, and 3% (47) noted lower likelihood (results not reported in table).

DISCUSSION {#s3}
==========

Across a diverse sample of 1435 participants, one-third more persons reported that they would be willing to collect specimens at home for SARS-CoV-2 testing if they experienced illness, compared with clinic-based testing. There was a hierarchy of willingness to test for SARS-CoV-2 that was decreased as the required degree of contact with health care systems increased: Home testing was most preferred, followed by drive-through testing, and then by laboratory- or clinic-based testing. If differences in reported willingness approximate those in actual willingness, the magnitude of the findings has considerable public health and clinical care implications. One indicator that the hypothetical may approach actual behavior is that participant preferences were consistent across COVID-19 symptomology levels: Persons currently experiencing COVID-19-related symptoms reported similarly lower willingness to seek drive-through and clinic-based SARS-CoV-2 testing as persons not currently experiencing symptoms. Preference differences were also constant across a wide variety of sociodemographic variables, which is important to note, considering the differential impact of SARS-CoV-2 on elderly persons \[[@CIT0022]\] and on African Americans, as reported in the media and confirmed by coroner's offices in Louisiana, Chicago, and Michigan \[[@CIT0023]\].

There are currently vast differences in how countries and jurisdictions are handling testing due to supply limitations. In Iceland, testing has been widely provided as a strategy to combat epidemic spread, and not surprisingly, this appears to be substantially contributing to their control of epidemic spread \[[@CIT0024]\]. With a combined approach for testing that included targeted recruitment of symptomatic persons or those in contact with symptomatic persons, an open invitation recruitment, and a random sample recruitment, Iceland tested \>22 000 persons using an in-person testing strategy \[[@CIT0024]\]. At-home self-collection of specimens is one of several options worthy of exploration to achieve similar gains in other settings. Home-based and drive-through testing strategies are promising in part because they may allow for rapid scale-up of newly validated approaches that may relieve supply chain problems. It is clear that, if sufficient laboratory capacity and supplies are available, increased testing using at-home specimen collection is critical for public health response for 3 reasons. First, it would facilitate increased initiation of contact tracing, a tool known to limit epidemic spread, by identifying people with mild symptoms and allowing public health authorities to test close contacts. Second, it would reduce the risk of disease transmission from clinical settings. Third, it would facilitate improved self-management, because mild and moderate COVID-19 symptoms are nonspecific. Persons receiving a formal SARS-CoV-2 diagnosis are likely to perform self-isolation activities with substantially more rigor than persons whose actions are informed only by their mild symptoms. Conversely, those determined to be uninfected would be anticipated to have reduced anxiety and to be able to continue with their lives without an unnecessary isolation period.

Given our finding that people were more willing to test with home specimen strategies, making such an option available might allow for earlier informed discussions with a clinician via an office visit or telemedicine regarding the optimal next steps in their care. This is especially relevant given media reports, confirmed by local health authorities, of the substantial increases of persons found dead in their homes in some cities in the United States compared with historic averages. In Detroit, there were more than 150 persons found dead in their homes in the first 10 days of April, compared with around 40 during that same period in the 3 years prior \[[@CIT0025]\]. In New York City in early April 2020, a spokesperson for the Department of Health confirmed that around 200 deaths per day have been observed in homes, compared with 20--25 deaths per day in 2019 \[[@CIT0026]\]. It is likely that many of the deceased did not have an opportunity to receive clinical care, a problem that could potentially be mitigated through more widespread and easily accessible testing.

Other authors have previously called for SARS-CoV-2 home testing, but mainly for its social distancing and reduced health care system burdens \[[@CIT0010], [@CIT0027]\]. Such calls can and have equally supported drive-through facilities \[[@CIT0010]\]. But our findings indicate that home collection was substantially preferred to drive-through methods, with \>20% more persons indicating willingness to complete a home test compared with a drive-through test. Drive-through testing venues may achieve benefits of viral transmission control but have lower benefits for increasing the demand for testing. These results are aligned with previous work that has found home specimen collection to be a highly preferred method of seeking clinical care \[[@CIT0007], [@CIT0028], [@CIT0029]\] and can be understood as part of an already ongoing move toward remote care facilitated by at-home specimen collection \[[@CIT0030]\]. An additional benefit is that home testing has the potential to reach persons with limited access to transportation or living far from available testing sites.

This national online survey study has a number of limitations. Participants volunteered to take an online survey regarding COVID-19, potentially skewing willingness values higher than among the general population. Moreover, reported willingness has been observed to overestimate uptake for other interventions \[[@CIT0034]\], and our findings are likely subject to similar bias. We do not think, however, that this would produce bias in the relative levels of support for the testing options presented. The cost of different SARS-CoV-2 testing strategies will likely vary, and if the health care system does not cover the cost of some test options, this would likely influence willingness to use that modality. In unpublished work, the sensitivity performance of saliva-based tests has been found to be higher than nasopharyngeal swabs in clinical settings \[[@CIT0035]\], yet a separate study identified poor sensitivity performance of saliva specimens in a community-based setting \[[@CIT0036]\]. Further studies for saliva as a specimen type in community settings are needed. The high overall preference for home testing, including for pharyngeal specimen collection, indicates that other home-based specimens such as anterior nares swab may likewise be highly acceptable. The convenience sample used in the present study may not represent the broader population in other ways, although the consistent and strong differences in preference across categories and item types indicate that this would likely have little influence on study results.

We found strong preferences for home testing options. Providing a home testing option is consistent with social distancing strategies, and patient-centered care strategies have been demonstrated to improve patient adherence to clinician recommendations. Home specimen collection and central laboratory testing can ease supply chain problems and be quickly scaled up for contact tracing use by public health authorities. Such home testing methods should be validated as soon as possible and brought to scale by clinicians and health systems.

Supplementary Data {#s4}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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Click here for additional data file.

###### 

Click here for additional data file.
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